drug · antibody

BRIUMVI

updated 2mo ago

by $TGTX TG THERAPEUTICS, INC.🔗 ChEMBL

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.

targets

B-lymphocyte antigen CD20

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

BRIUMVI

trade names

Briumvi

generic

UBLITUXIMAB-XIIY

MOA

12.1 Mechanism of Action The precise mechanism by which ublituximab-xiiy exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ublituximab-xiiy results in cell lysis through mechanisms including antibody-dependent cellular cytolysis and complement-dependent cytolysis.

indication

1 INDICATIONS AND USAGE BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 , 14 ).

BRIUMVI

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside